Business Context and Reporting Period
This Form 6-K filing by Novartis AG, dated May 22, 2007, reports on a significant legal development regarding the company's high blood pressure medicine, Lotrel. The filing details a US federal court ruling extending a temporary restraining order against Teva Pharmaceuticals, which had received FDA approval for a generic version of the drug. While the order halts further shipments of the generic, it permits the sale of units already distributed prior to the court's initial halt order.
Key Financial Metrics
- Lotrel 2006 Sales: USD 1.35 billion (US market only).
- Group 2006 Net Sales: USD 37.0 billion.
- Group 2006 Net Income: USD 7.2 billion.
- Group 2006 R&D Investment: Approximately USD 5.4 billion.
- Patent Expiry: The US patent for Lotrel remains valid until December 2017.
Material Changes and Legal Developments
The primary material change involves the status of Lotrel sales in the US. A US District Court Judge extended a temporary restraining order against Teva Pharmaceuticals until May 29, 2007, preventing further shipments of the generic drug. However, Teva is permitted to sell generic copies already shipped to distributors and customers before the initial court order on May 19. Additionally, the court prevented Novartis from launching an "authorized generic" version of Lotrel until the next hearing on May 29. A hearing on a preliminary injunction is scheduled for July 11.
Guidance, Outlook, and Risks
Novartis is currently evaluating the potential impact of Teva's actions on full-year 2007 net sales, operating income, and net income results. The company states it will continue to vigorously defend its intellectual property rights and the validity of the Lotrel patent. The filing includes a disclaimer regarding forward-looking statements, noting that actual results may vary materially due to uncertainties in US patent law, the litigation process, and the ability to maintain proprietary protection. There is no guarantee that the injunction will be maintained or that Novartis will succeed in the underlying litigation.
Investor Verification Checklist
- Verify the volume of generic Lotrel units Teva was allowed to sell prior to the May 19 court order.
- Monitor the outcome of the preliminary injunction hearing scheduled for July 11, 2007.
- Assess the specific financial impact on Q2 and full-year 2007 guidance once Novartis completes its evaluation.
- Review the status of the "authorized generic" launch restriction and its potential revenue implications.